Oksana Koneva

Nautilus Biotechnology launches grant for no-cost AKT1 and EGFR proteoform analysis at ASHG2026

Nautilus Biotechnology launches grant for no-cost AKT1 and EGFR proteoform analysis at ASHG2026
Nautilus Biotechnology announces Voyager grant

Nautilus Biotechnology has announced an opportunity for researchers to access its Voyager platform at no charge during ASHG2026. The company is inviting interested parties to explore either AKT1 or EGFR proteoforms as part of its Iterative Mapping Grant Program.

Applicants can apply using the provided link and are encouraged to visit booth 1425 at the event for further information or inquiries.

Nautilus Biotechnology previously launched a grant program allowing researchers to analyze AKT1 or EGFR proteoforms in oncology studies at no cost, according to company announcements. The firm is also participating in the ARPA-H backed SEEDS consortium to study disease-related protein misfolding mechanisms, as detailed in an earlier update. These initiatives continue Nautilus’s strategy of supporting academic research through funded access to its proteomics technology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.